STAT+: Tracking the FDA expert review of Replimune’s melanoma treatment
STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.
<p>STAT is live-blogging a meeting of FDA experts to review Replimune’s experimental melanoma drug, RP1.</p>